Skip Navigation


JAC Advance Access originally published online on May 29, 2003
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
52/1/18    most recent
dkg286v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (13)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Finlay, J.
Right arrow Articles by Poupard, J. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Finlay, J.
Right arrow Articles by Poupard, J. A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


Journal of Antimicrobial Chemotherapy (2003) 52, 18-23
© 2003 The British Society for Antimicrobial Chemotherapy

Review Article

A review of the antimicrobial activity of clavulanate

Jane Finlay*, Linda Miller and James A. Poupard

GlaxoSmithKline, 1250 South Collegeville Road, Collegeville, PA 19426-0989, USA

Clavulanate is a broad-spectrum ß-lactamase inhibitor, with activity against many of the chromosomally and plasmid-mediated ß-lactamases of both Gram-positive and Gram-negative bacteria. Although clavulanate has minimal antibacterial activity in vitro, accumulating evidence suggests that it may have an effect on pathogenic bacteria regardless of ß-lactamase production. Like other ß-lactams, clavulanate has been shown to bind to penicillin-binding proteins (PBPs) in Gram-positive and Gram-negative bacteria. It was found to bind selectively to PBP3 in Streptococcus pneumoniae. It has been suggested that complementary binding to different PBPs and subsequent effects on autolysis contribute to the enhancement of the activity of other ß-lactams by clavulanate. In addition, co-amoxiclav has been shown to enhance the intracellular killing functions of human polymorphonuclear cells (PMNs) in studies undertaken with ß-lactamase-producing and non-ß-lactamase-producing strains of bacteria. These data from in vitro and cell culture systems have been reflected in vivo, where clavulanate enhanced the activity of amoxicillin against non-ß-lactamase-producing organisms. Further studies are required to determine whether the effects seen within in vitro and in vivo animal studies have clinical significance.

Keywords: ß-lactamase, clavulanate, Streptococcus pneumoniae

* Corresponding author. Tel: +1-610-917-6275; Fax: +1-610-917-4830; E-mail: Jane_Finlay-1{at}gsk.com


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Antimicrob. Agents Chemother.Home page
A. Beceiro, R. Lopez-Rojas, J. Dominguez-Herrera, F. Docobo-Perez, G. Bou, J. Pachon, and the Spanish Network for Research in Infectious Dis
In Vitro Activity and In Vivo Efficacy of Clavulanic Acid against Acinetobacter baumannii
Antimicrob. Agents Chemother., October 1, 2009; 53(10): 4298 - 4304.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
H.-K. Lee, S. J. Brown, H. Rosen, and P. S. Tobias
Application of beta-Lactamase Enzyme Complementation to the High-Throughput Screening of Toll-Like Receptor Signaling Inhibitors
Mol. Pharmacol., October 1, 2007; 72(4): 868 - 875.
[Abstract] [Full Text] [PDF]

Home page
 ScienceHome page
M. Kawakubo, Y. Ito, Y. Okimura, M. Kobayashi, K. Sakura, S. Kasama, M. N. Fukuda, M. Fukuda, T. Katsuyama, and J. Nakayama
Natural Antibiotic Function of a Human Gastric Mucin Against Helicobacter pylori Infection
Science, August 13, 2004; 305(5686): 1003 - 1006.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.